Vojta Reflex Versus Lung Squeezing Technique in Respiratory Distress Preterm Neonate
Launched by BENI-SUEF UNIVERSITY · May 19, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different treatments for premature babies (neonates) who are experiencing respiratory distress syndrome, a condition that makes it hard for them to breathe. The researchers want to find out if a method called Vojta therapy is more effective than another method called lung squeezing technique in helping these babies breathe better and improving their oxygen levels. They will also look at how these treatments affect the babies' hospital stay duration and their overall breathing scores.
To participate in this study, babies must be between 28 and 36 weeks of gestation and currently receiving oxygen therapy in the neonatal intensive care unit (NICU). They should not have any other serious medical conditions apart from respiratory distress syndrome. Over three weeks, eligible babies will receive standard chest physical therapy along with either Vojta therapy or the lung squeezing technique, while a control group will only receive the standard therapy. This trial aims to improve care for these vulnerable infants by comparing the effectiveness of the two techniques.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * preterm neonates will be:
- • Ranging from 28-36 weeks of gestation admitted to NICU with diagnosis of respiratory distress syndrome (RDS)on oxygen therapy.
- • Medically free from any other diseases except RDS.
- • On CPAP for respiratory support.
- Exclusion Criteria:
- * Preterm neonates who meet one of the following criteria will be excluded:
- • Musculoskeletal disorders
- • Encephalopathy
- • Recent surgery
- • Neonates with respiratory and cardiac congenital anomalies
- • mechanically ventilated
- • genetic syndromes
- • segmental or lobar collapse confirmed on chest X-ray
- • congenital malformation
- • asphyxia at birth
- • treatment with neurotrophic drugs
- • intraventricular hemorrhage \< 2 grade
About Beni Suef University
Beni-Suef University is a prominent academic institution in Egypt dedicated to advancing medical research and clinical trials aimed at improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university fosters a multidisciplinary approach to research, engaging faculty, students, and healthcare professionals in the pursuit of scientific knowledge. The institution is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that all clinical trials conducted under its auspices are designed to enhance patient care and contribute to the global body of medical research. Through its initiatives, Beni-Suef University aims to translate research findings into practical applications that benefit communities locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beni Suef,Egypt, , Egypt
Patients applied
Trial Officials
Sherine H Mehani, professor
Principal Investigator
Beni-Suef University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported